Regado Biosciences | Evaluate

NASH craze lives on, despite the unknowns

December 24, 2014

Cyclacel and Neovacs enter the graveyard shift

August 26, 2014

Regado pays steep price to avert full phase III cost

July 03, 2014

Forget the binary outcome; Regado faces a bigger problem

April 14, 2014

Lombard postpones IPO as US indices decline

January 06, 2014

Fast times in biotech push IPO count to new highs

September 17, 2013

Regado remains a huge binary bet despite share price bump

February 05, 2010

EP Vantage Interview - Regado seeking solution to clotting conundrum